Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
December 15, 2023 08:30 ET
|
Femasys Inc.
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since...
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
November 30, 2023 08:30 ET
|
Femasys Inc.
ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
November 28, 2023 08:30 ET
|
Femasys Inc.
- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a...
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023 07:30 ET
|
Femasys Inc.
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to...
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
November 14, 2023 07:00 ET
|
Femasys Inc.
- 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization - - Patient enrollment has commenced in landmark, pivotal FINALE...
Femasys Inc. EU MDR Final Audit Successfully Completed
October 26, 2023 08:30 ET
|
Femasys Inc.
– Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys’ compliance with the highest required...
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
October 25, 2023 08:00 ET
|
Femasys Inc.
ATLANTA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
October 11, 2023 07:00 ET
|
Femasys Inc.
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
October 04, 2023 08:30 ET
|
Femasys Inc.
ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office,...
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
October 03, 2023 08:30 ET
|
Femasys Inc.
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed to bringing innovative solutions to women around...